JPH05503952A
(ja)
*
|
1989-09-08 |
1993-06-24 |
アルファ ベータ テクノロジー,インコーポレイティッド |
可溶性グルカン類の製造方法
|
US5811542A
(en)
*
|
1989-09-08 |
1998-09-22 |
Alpha-Beta Technology, Inc. |
Method for producing soluble glucans
|
US5622939A
(en)
*
|
1992-08-21 |
1997-04-22 |
Alpha-Beta Technology, Inc. |
Glucan preparation
|
FR2655267B1
(fr)
*
|
1989-12-04 |
1992-04-03 |
Roussel Uclaf |
Nouveau derive sulfate du galactanne extrait de klebsiella, procede de preparation, application a titre de medicaments et compositions pharmaceutiques le renfermant.
|
JPH0665649B2
(ja)
*
|
1991-02-01 |
1994-08-24 |
台糖株式会社 |
甲殻類の生体防御能増強剤、感染症予防ワクチン及び飼料
|
FR2674755B1
(fr)
*
|
1991-04-05 |
1995-02-03 |
Thorel Jean Noel |
Nouvelles compositions medicamenteuses immunostimulatrices.
|
JP3522772B2
(ja)
*
|
1991-05-21 |
2004-04-26 |
台糖株式会社 |
ワクチンの免疫効果増強剤
|
IL104382A0
(en)
*
|
1992-01-17 |
1993-05-13 |
Solvay Animal Health Inc |
Vaccine containing acemannan as an adjuvant
|
EP0640348A1
(en)
*
|
1993-07-26 |
1995-03-01 |
Akzo Nobel N.V. |
Oil-based and water-based adjuvant mixture
|
AU698176B2
(en)
*
|
1993-07-28 |
1998-10-29 |
Cis Bio International |
Radiolabelled glucans
|
US5919466A
(en)
*
|
1993-10-01 |
1999-07-06 |
Gerbu Biotechnik Gmbh |
Method for improving the yield of immunoantibodies in the vaccination of animals and humans
|
AUPM572294A0
(en)
*
|
1994-05-18 |
1994-06-09 |
Vaccine Technologies Pty. Ltd. |
Delivery vehicle for bioactive molecule
|
US5714163A
(en)
*
|
1994-06-27 |
1998-02-03 |
Nexstar Pharmaceuticals, Inc. |
Vinca alkaloid vesicles with enhanced efficacy and tumor targeting properties
|
US5622940A
(en)
*
|
1994-07-14 |
1997-04-22 |
Alpha-Beta Technology |
Inhibition of infection-stimulated oral tissue destruction by β(1,3)-glucan
|
US5576015A
(en)
*
|
1995-03-02 |
1996-11-19 |
Donzis; Byron A. |
Substantially purified beta (1,3) finely ground yeast cell wall glucan composition with dermatological and nutritional uses
|
AUPN166195A0
(en)
*
|
1995-03-13 |
1995-04-06 |
Norvet Research Pty Limited |
Process for glucan extraction
|
US5785975A
(en)
*
|
1995-06-26 |
1998-07-28 |
Research Triangle Pharmaceuticals |
Adjuvant compositions and vaccine formulations comprising same
|
JP2001523216A
(ja)
*
|
1995-06-26 |
2001-11-20 |
リサーチ.トライアングル.ファーマシューティカルズ |
新規のアジュバント組成物と、それからなるワクチン製剤
|
ATE399022T1
(de)
*
|
1995-10-20 |
2008-07-15 |
Univ Nebraska |
Zusammensetzung und verfahren zur verstärkung der immunantwort antigen-präsentierender zellen
|
US20080286228A1
(en)
*
|
1995-10-20 |
2008-11-20 |
Tarantolo Stefano R |
Compositions and methods for enhancing immune responses mediated by antigen-presenting cells
|
US6084092A
(en)
|
1997-01-31 |
2000-07-04 |
The Collaborative Group, Ltd. |
β(1-3)-glucan diagnostic assays
|
US6110692A
(en)
*
|
1996-05-01 |
2000-08-29 |
The Collaborative Group, Ltd. |
Receptor for underivatized aqueous soluble β(1-3)-glucan
|
JPH10139670A
(ja)
*
|
1996-11-11 |
1998-05-26 |
Terukuni Yakida |
インターロイキン12誘導物質及び医薬組成物
|
US6797276B1
(en)
*
|
1996-11-14 |
2004-09-28 |
The United States Of America As Represented By The Secretary Of The Army |
Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
|
US20060002949A1
(en)
*
|
1996-11-14 |
2006-01-05 |
Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. |
Transcutaneous immunization without heterologous adjuvant
|
US6413715B2
(en)
|
1997-01-31 |
2002-07-02 |
The Collaborative Group |
β(1-3)-glucan diagnostic assays
|
US5786343A
(en)
*
|
1997-03-05 |
1998-07-28 |
Immudyne, Inc. |
Phagocytosis activator compositions and their use
|
DE19737481A1
(de)
*
|
1997-08-28 |
1999-03-04 |
Hoechst Ag |
Sphärische lineare Polysaccharide enthaltende Mikropartikel
|
IL135148A0
(en)
*
|
1997-10-03 |
2001-05-20 |
Galenica Pharmaceuticals Inc |
A polysaccharide conjugate and pharmaceutical compositions containing the same
|
US6756361B1
(en)
*
|
1997-10-14 |
2004-06-29 |
Nabi |
Enterococcus antigens and vaccines
|
EP1039881A1
(en)
*
|
1997-12-18 |
2000-10-04 |
Ato B.V. |
Composition for the controlled release of active compounds
|
US6573245B1
(en)
|
1998-04-28 |
2003-06-03 |
Galenica Pharmaceuticals, Inc. |
Modified polysaccharide adjuvant-protein antigen conjugates, the preparation thereof and the use thereof
|
CA2342832A1
(en)
*
|
1998-09-04 |
2000-03-16 |
Powderject Research Limited |
Immunodiagnostics using particle delivery methods
|
US7030101B2
(en)
|
1998-09-14 |
2006-04-18 |
Nabi Biopharmaceuticals |
Compositions of β-glucans and specific antibodies
|
DE69940371D1
(de)
*
|
1998-09-14 |
2009-03-19 |
Nabi Biopharmaceuticals Rockvi |
Beta-glucan enthaltende zusammenstellungen und spezifische immunoglobuline
|
AU6261999A
(en)
*
|
1998-09-25 |
2000-04-17 |
Collaborative Group, Ltd., The |
Very high molecular weight beta-glucans
|
US6369216B1
(en)
|
1998-09-25 |
2002-04-09 |
Biopolymer Engineering Pharmaceutical, Inc. |
Very high molecular weight β-glucans
|
US6541678B2
(en)
*
|
1999-09-27 |
2003-04-01 |
Brennen Medical, Inc. |
Immunostimulating coating for surgical devices
|
US20020009463A1
(en)
*
|
2000-02-23 |
2002-01-24 |
Jan Raa |
Novel, non-antigenic, mucosal adjuvant formulation which enhances the effects of substances, including vaccine antigens, in contact with mucosal body surfaces
|
US7906492B2
(en)
*
|
2001-01-16 |
2011-03-15 |
Sloan-Kettering Institute For Cancer Research |
Therapy-enhancing glucan
|
US7507724B2
(en)
*
|
2001-01-16 |
2009-03-24 |
Sloan-Kettering Institute For Cancer Research |
Therapy-enhancing glucan
|
CA2434938C
(en)
*
|
2001-01-16 |
2012-02-28 |
Sloan-Kettering Institute For Cancer Research |
Compositions of glucan and a monoclonal antibody which exhibit an enhancement of the anti tumor activity of the antibody
|
PT1372708E
(pt)
|
2001-02-13 |
2008-09-29 |
Us Gov Sec Army |
Vacina para imunização transcutânea
|
KR20090057480A
(ko)
*
|
2001-04-27 |
2009-06-05 |
아지노모토 가부시키가이샤 |
면역강화제
|
NO20014256D0
(no)
*
|
2001-09-03 |
2001-09-03 |
Bjoern Kristiansen |
Fremstilling av immunstimulerende forbindelse
|
US7786094B2
(en)
*
|
2001-10-09 |
2010-08-31 |
Biopolymer Engineering, Inc. |
Use of beta-glucans against biological warfare weapons and pathogens including anthrax
|
ES2294180T3
(es)
*
|
2001-12-11 |
2008-04-01 |
Ceapro Inc. |
Composiciones de beta-glucano de cereales, metodos de preparacion y usos de las mismas.
|
AU2003257007A1
(en)
*
|
2002-08-01 |
2004-02-23 |
Immusonic, Inc. |
Beta-glucan containing composites, methods for manufacturing and for using such composites
|
EP1545208A4
(en)
*
|
2002-08-13 |
2006-04-12 |
Biopolymer Engineering Inc |
METHODS OF USING BETA-GLUCAN AS RADIOPROTECTIVE AGENT
|
EP2181711A1
(en)
*
|
2002-09-04 |
2010-05-05 |
Biopolymer Engineering, Inc. |
Cancer therapy using whole glucan particles and antibodies
|
US20060165700A1
(en)
*
|
2002-09-04 |
2006-07-27 |
Ostroff Gary R |
Cancer therapy using whole glucan particles and antibodies
|
US20050232986A1
(en)
*
|
2003-12-17 |
2005-10-20 |
David Brown |
Dosage form containing promethazine and another drug
|
US9492541B2
(en)
*
|
2004-09-14 |
2016-11-15 |
Sovereign Pharmaceuticals, Llc |
Phenylepherine containing dosage form
|
US20050266032A1
(en)
*
|
2003-12-17 |
2005-12-01 |
Sovereign Pharmaceuticals, Ltd. |
Dosage form containing multiple drugs
|
US20050281875A1
(en)
*
|
2003-12-17 |
2005-12-22 |
Sovereign Pharmaceuticals, Ltd. |
Promethazine containing dosage form
|
US20060029664A1
(en)
*
|
2004-08-04 |
2006-02-09 |
Sovereign Pharmaceuticals, Ltd. |
Dosage form containing carbetapentane and another drug
|
US20050232987A1
(en)
*
|
2004-03-12 |
2005-10-20 |
Viswanathan Srinivasan |
Dosage form containing a morphine derivative and another drug
|
EP1711058B1
(en)
|
2004-01-23 |
2021-09-15 |
Eden Research Plc |
Methods of killing nematodes comprising the application of a terpene component
|
US20050208145A1
(en)
*
|
2004-03-19 |
2005-09-22 |
Thava Vasanthan |
Grain fiber compositions and methods of use
|
US20050220846A1
(en)
|
2004-04-05 |
2005-10-06 |
Puntenney Steven B |
Use of beta-1,3 (4)-endoglucanohydrolase, beta-1,3 (4) glucan, diatomaceous earth, mineral clay and glucomannan to augment immune function
|
SI2338332T1
(sl)
*
|
2004-05-20 |
2014-06-30 |
Eden Research Plc |
Votli delec glukana ali votli delec stene celice, ki enkapsulira komponento terpena
|
US7740861B2
(en)
*
|
2004-06-16 |
2010-06-22 |
University Of Massachusetts |
Drug delivery product and methods
|
US7514085B2
(en)
|
2004-07-16 |
2009-04-07 |
Medimush A/S |
Immune modulating compounds from fungi
|
US20070003622A1
(en)
*
|
2004-12-16 |
2007-01-04 |
Sovereign Pharmaceuticals, Ltd. |
Diphenhydramine containing dosage form
|
US9592197B2
(en)
*
|
2004-12-16 |
2017-03-14 |
Sovereign Pharmaceuticals, Llc |
Dosage form containing diphenhydramine and another drug
|
JP5302537B2
(ja)
*
|
2004-09-17 |
2013-10-02 |
ユニバーシティ オブ マサチューセッツ |
リソソーム酵素欠損症のための組成物およびそれらの使用
|
WO2006121803A1
(en)
|
2005-05-05 |
2006-11-16 |
Sensient Flavors Inc. |
Production of beta-glucans and mannans
|
US9072776B2
(en)
|
2005-06-15 |
2015-07-07 |
Glycanova As |
Anti-cancer combination treatment and kit-of-parts
|
WO2006133708A1
(en)
*
|
2005-06-15 |
2006-12-21 |
Medimush A/S |
Bioactive agents produced by submerged cultivation of a basidiomycete cell
|
AU2006306228A1
(en)
*
|
2005-10-24 |
2007-05-03 |
University Of Massachusetts |
Compositions and their uses for gene therapy of bone conditions
|
WO2007063267A1
(en)
|
2005-11-30 |
2007-06-07 |
Eden Research Plc |
Terpene-containing compositions and methods of making and using them
|
WO2007063268A1
(en)
|
2005-11-30 |
2007-06-07 |
Eden Research Plc |
Compositions and methods comprising terpenes or terpene mixtures selected from thymol, eugenol, geraniol, citral, and l-carvone
|
US8323644B2
(en)
|
2006-01-17 |
2012-12-04 |
Sloan-Kettering Institute For Cancer Research |
Therapy-enhancing glucan
|
US20090053221A1
(en)
*
|
2006-01-17 |
2009-02-26 |
Cheung Nai-Kong V |
Immune response enhancing glucan
|
US20080044438A1
(en)
*
|
2006-03-17 |
2008-02-21 |
Ostroff Gary R |
Yeast Cell Particles As Oral Delivery Vehicles For Antigens
|
RU2490279C2
(ru)
|
2006-06-15 |
2013-08-20 |
Байотера, Инк. |
Композиции глюкана
|
WO2008027580A2
(en)
*
|
2006-09-01 |
2008-03-06 |
University Of Louisville |
PARTICULATE β-GLUCAN COMPOSITIONS FOR REGULATING DENDRITIC CELLS
|
US20080063650A1
(en)
*
|
2006-09-01 |
2008-03-13 |
Jun Yan |
mCRP antagonists and their uses
|
US20090022799A1
(en)
*
|
2006-10-06 |
2009-01-22 |
Shikha Pramanik Barman |
Compositions that contain beta-glucan to be used for the prevention and treatment of disease and methods for their use
|
EP2066294B9
(en)
*
|
2006-11-06 |
2013-04-10 |
Whitehead Institute |
Immunomodulating compositions and methods of use thereof
|
US9457047B2
(en)
|
2006-11-06 |
2016-10-04 |
Whitehead Institute |
Immunomodulating compositions and methods of use thereof
|
WO2009058913A2
(en)
*
|
2007-10-29 |
2009-05-07 |
University Of Massachusetts |
Encapsulated nanoparticles for nucleic acid delivery
|
US9095620B2
(en)
*
|
2008-03-12 |
2015-08-04 |
Nektar Therapeutics |
Reagents
|
WO2009114153A1
(en)
|
2008-03-12 |
2009-09-17 |
Nektar Therapeutics |
Oligomer-foscarnet conjugates
|
EP2105145A1
(en)
*
|
2008-03-27 |
2009-09-30 |
ETH Zürich |
Method for muscle-specific delivery lipid-conjugated oligonucleotides
|
US20110059921A1
(en)
*
|
2008-03-27 |
2011-03-10 |
Ektar Therapeutics |
Oligomer-Nitrogenous Base Conjugates
|
US9233165B2
(en)
*
|
2008-04-11 |
2016-01-12 |
Nektar Therapeutics |
Oligomer-aryloxy-substituted propanamine conjugates
|
US8324366B2
(en)
|
2008-04-29 |
2012-12-04 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for delivering RNAI using lipoproteins
|
WO2010008582A2
(en)
|
2008-07-18 |
2010-01-21 |
Rxi Pharmaceuticals Corporation |
Phagocytic cell drug delivery system
|
WO2010014258A2
(en)
*
|
2008-08-01 |
2010-02-04 |
Nektar Therapeutics Al, Corporation |
Conjugates having a releasable linkage
|
CA2732508C
(en)
|
2008-08-11 |
2016-03-15 |
Nektar Therapeutics |
Multi-arm polymeric alkanoate conjugates
|
WO2010021718A1
(en)
|
2008-08-19 |
2010-02-25 |
Nektar Therapeutics |
Complexes of small-interfering nucleic acids
|
US8318693B2
(en)
|
2008-09-02 |
2012-11-27 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of mutant EGFR gene
|
WO2010033215A2
(en)
*
|
2008-09-19 |
2010-03-25 |
Nektar Therapeutics |
Polymer conjugates of aod-like peptides
|
US20110206633A1
(en)
*
|
2008-09-19 |
2011-08-25 |
Nektar Therapectics |
Polymer conjugates of cd-np peptides
|
US20110171166A1
(en)
*
|
2008-09-19 |
2011-07-14 |
Nektar Therapeutics |
Polymer conjugates of osteocalcin peptides
|
WO2010033224A1
(en)
*
|
2008-09-19 |
2010-03-25 |
Nektar Therapeutics |
Polymer conjugates of kiss1 peptides
|
EP2344199A1
(en)
*
|
2008-09-19 |
2011-07-20 |
Nektar Therapeutics |
Polymer conjugates of thymosin alpha 1 peptides
|
WO2010033205A1
(en)
*
|
2008-09-19 |
2010-03-25 |
Nektar Therapeutics |
Polymer conjugates of v681-like peptides
|
US20110171164A1
(en)
*
|
2008-09-19 |
2011-07-14 |
Nektar Therapeutics |
Polymer conjugates of glp-2-like peptides
|
US20110165112A1
(en)
*
|
2008-09-19 |
2011-07-07 |
Nektar Therapeutics |
Polymer conjugates of c-peptides
|
WO2010033240A2
(en)
|
2008-09-19 |
2010-03-25 |
Nektar Therapeutics |
Carbohydrate-based drug delivery polymers and conjugates thereof
|
EP2334337A1
(en)
*
|
2008-09-19 |
2011-06-22 |
Nektar Therapeutics |
Polymer conjugates of opioid growth factor peptides
|
WO2010078536A1
(en)
|
2009-01-05 |
2010-07-08 |
Rxi Pharmaceuticals Corporation |
Inhibition of pcsk9 through rnai
|
WO2010099200A1
(en)
|
2009-02-24 |
2010-09-02 |
Nektar Therapeutics |
Oligomer-amino acid conjugates
|
US20120041051A1
(en)
|
2009-02-26 |
2012-02-16 |
Kevin Fitzgerald |
Compositions And Methods For Inhibiting Expression Of MIG-12 Gene
|
US8530492B2
(en)
|
2009-04-17 |
2013-09-10 |
Nektar Therapeutics |
Oligomer-protein tyrosine kinase inhibitor conjugates
|
WO2010120388A1
(en)
|
2009-04-17 |
2010-10-21 |
Nektar Therapeutics |
Oligomer-protein tyrosine kinase inhibitor conjugates
|
EP2416652B1
(en)
|
2009-05-05 |
2018-11-07 |
Arbutus Biopharma Corporation |
Methods of delivering oligonucleotides to immune cells
|
KR101799113B1
(ko)
|
2009-05-13 |
2017-11-17 |
넥타르 테라퓨틱스 |
올리고머를 함유하는 치환된 방향족 트리아진 화합물
|
US8785661B2
(en)
|
2009-05-13 |
2014-07-22 |
Nektar Therapeutics |
Oligome-containing pyrrolidine compounds
|
WO2011035065A1
(en)
|
2009-09-17 |
2011-03-24 |
Nektar Therapeutics |
Monoconjugated chitosans as delivery agents for small interfering nucleic acids
|
WO2011061144A2
(en)
|
2009-11-20 |
2011-05-26 |
Basf Se |
The present invention relates to the use of beta-(1, 3)- beta-(1, 4) glucan with an average molecular weight of from 5.000 to 150.000 da for the increase of synthesis of collagen
|
CZ302789B6
(cs)
*
|
2009-11-25 |
2011-11-09 |
Zentiva, K. S. |
Zpusob zvýšení rozpustnosti farmaceuticky aktivních látek a cílený (kontrolovaný) transport do streva
|
WO2011073326A2
(en)
|
2009-12-18 |
2011-06-23 |
Novartis Ag |
Organic compositions to treat hsf1-related diseases
|
WO2011103559A1
(en)
|
2010-02-22 |
2011-08-25 |
Nektar Therapeutics |
Oligomer modified diaromatic substituted compounds
|
EP2550001B1
(en)
|
2010-03-24 |
2019-05-22 |
Phio Pharmaceuticals Corp. |
Rna interference in ocular indications
|
EP3560503B1
(en)
|
2010-03-24 |
2021-11-17 |
Phio Pharmaceuticals Corp. |
Rna interference in dermal and fibrotic indications
|
WO2011131707A1
(en)
|
2010-04-23 |
2011-10-27 |
Novartis Ag |
ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
|
US20110293784A1
(en)
|
2010-05-28 |
2011-12-01 |
Anja Wittke |
Milk-based nutritional compositions
|
US9944671B2
(en)
|
2010-06-02 |
2018-04-17 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods directed to treating liver fibrosis
|
WO2012024229A1
(en)
|
2010-08-14 |
2012-02-23 |
University Of Massachusetts |
Yeast cell wall particle for receptor-targeted nanoparticle delivery
|
WO2012051551A1
(en)
|
2010-10-15 |
2012-04-19 |
Nektar Therapeutics |
N-optionally substituted aryl-2-oligomer-3-alkoxypropionamides
|
EP2648763A4
(en)
|
2010-12-10 |
2014-05-14 |
Alnylam Pharmaceuticals Inc |
COMPOSITIONS AND METHODS FOR EXPRESSION INHIBITION OF GENES KLF-1 AND BCL11A
|
EP2649182A4
(en)
|
2010-12-10 |
2015-05-06 |
Alnylam Pharmaceuticals Inc |
COMPOSITIONS AND METHOD FOR INCREASING AN ERYTHROPOIETIN (EPO) PREPARATION
|
WO2012082995A1
(en)
|
2010-12-15 |
2012-06-21 |
Nektar Therapeutics |
Oligomer-containing hydantoin compounds
|
WO2012083153A1
(en)
|
2010-12-16 |
2012-06-21 |
Nektar Therapeutics |
Oligomer-containing apremilast moiety compounds
|
US20130331443A1
(en)
|
2010-12-22 |
2013-12-12 |
Nektar Therapeutics |
Multi-arm polymeric prodrug conjugates of taxane-based compounds
|
WO2012088433A1
(en)
|
2010-12-22 |
2012-06-28 |
Nektar Therapeutics |
Deuterated and/or fluorinated taxane derivatives
|
US10894087B2
(en)
|
2010-12-22 |
2021-01-19 |
Nektar Therapeutics |
Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
|
JP6009457B2
(ja)
|
2010-12-23 |
2016-10-19 |
ネクター セラピューティクス |
ポリマー−デスエチルスニチニブコンジュゲート
|
EP2654799B1
(en)
|
2010-12-23 |
2017-11-08 |
Nektar Therapeutics |
Polymer-sunitinib conjugates
|
US9943605B2
(en)
|
2010-12-23 |
2018-04-17 |
Nektar Therapeutics |
Polymer-semaxanib moiety conjugates
|
RU2702501C2
(ru)
|
2011-03-29 |
2019-10-08 |
Элнилэм Фармасьютикалз, Инк. |
Композиции и способы ингибирования экспрессии гена tmprss6
|
AU2012272970A1
(en)
|
2011-06-21 |
2014-02-06 |
Alnylam Pharmaceuticals, Inc. |
Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
|
CA2839896A1
(en)
|
2011-06-21 |
2012-12-27 |
Alnylam Pharmaceuticals, Inc. |
Assays and methods for determining activity of a therapeutic agent in a subject
|
WO2012178033A2
(en)
|
2011-06-23 |
2012-12-27 |
Alnylam Pharmaceuticals, Inc. |
Serpina1 sirnas: compositions of matter and methods of treatment
|
US20140328811A1
(en)
|
2011-08-01 |
2014-11-06 |
Alnylam Pharmaceuticals, Inc. |
Method for improving the success rate of hematopoietic stem cell transplants
|
CA3185394A1
(en)
|
2011-09-02 |
2013-03-07 |
Arrowhead Pharmaceuticals, Inc. |
Organic compositions to treat hsf1-related diseases
|
US10023862B2
(en)
|
2012-01-09 |
2018-07-17 |
Arrowhead Pharmaceuticals, Inc. |
Organic compositions to treat beta-catenin-related diseases
|
US9133461B2
(en)
|
2012-04-10 |
2015-09-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the ALAS1 gene
|
US9127274B2
(en)
|
2012-04-26 |
2015-09-08 |
Alnylam Pharmaceuticals, Inc. |
Serpinc1 iRNA compositions and methods of use thereof
|
EP3409280B1
(en)
*
|
2012-07-05 |
2021-04-14 |
Nutramax Laboratories, Inc. |
Compositions comprising a sulforaphane and milk thistle extract or powder
|
US9744193B2
(en)
|
2012-09-06 |
2017-08-29 |
Orbis Health Solutions Llc |
Tumor lysate loaded particles
|
JP6265998B2
(ja)
|
2012-09-17 |
2018-01-24 |
ネクター セラピューティクス |
オリゴマー含有ベンズアミド系化合物
|
GB201220940D0
(en)
|
2012-11-21 |
2013-01-02 |
Eden Research Plc |
Method P
|
CN104981258B
(zh)
|
2012-12-12 |
2017-10-20 |
奥比思健康解决方案有限责任公司 |
用于组织再生的组合物、其制备方法及其用途
|
WO2014130922A1
(en)
|
2013-02-25 |
2014-08-28 |
Trustees Of Boston University |
Compositions and methods for treating fungal infections
|
KR102605775B1
(ko)
|
2013-03-14 |
2023-11-29 |
알닐람 파마슈티칼스 인코포레이티드 |
보체 성분 C5 iRNA 조성물 및 그 이용 방법
|
AR096203A1
(es)
|
2013-05-06 |
2015-12-16 |
Alnylam Pharmaceuticals Inc |
Dosificaciones y métodos para administrar moléculas de ácido nucleico formuladas en lípidos
|
US10077444B2
(en)
|
2013-10-02 |
2018-09-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the LECT2 gene
|
PE20161130A1
(es)
|
2013-10-04 |
2016-11-25 |
Icahn School Med Mount Sinai |
Composiciones y metodos para inhibir la expresion del gen alas1
|
BR112016007130B1
(pt)
*
|
2013-10-09 |
2023-01-31 |
Toray Industries, Inc |
Ss-glucana modificada, medicamento, vacina e uso de uma ss-glucana modificada ou de um medicamento
|
BR112016011711A2
(pt)
|
2013-11-21 |
2017-08-08 |
Eden Research Plc |
Composição pesticida, método para prepará-la e método para matar insetos
|
EP3077050B1
(en)
|
2013-12-04 |
2020-10-21 |
Phio Pharmaceuticals Corp. |
Methods for treatment of wound healing utilizing chemically modified oligonucleotides
|
WO2015092819A2
(en)
|
2013-12-21 |
2015-06-25 |
Nektar Therapeutics (India) Pvt. Ltd. |
Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5- amine
|
CN113057959A
(zh)
|
2014-02-11 |
2021-07-02 |
阿尔尼拉姆医药品有限公司 |
己酮糖激酶(KHK)iRNA组合物及其使用方法
|
PL3110437T3
(pl)
|
2014-02-12 |
2018-04-30 |
Omnigen Research, Llc |
Kompozycja i sposób wspomagania obniżania poziomu stresu cieplnego u zwierząt
|
US10166195B2
(en)
|
2014-03-05 |
2019-01-01 |
Orbis Health Solutions, Llc |
Vaccine delivery systems using yeast cell wall particles
|
WO2015168108A2
(en)
|
2014-04-28 |
2015-11-05 |
Rxi Pharmaceuticals Corporation |
Methods for treating cancer using nucleic targeting mdm2 or mycn
|
JP2017514908A
(ja)
|
2014-05-01 |
2017-06-08 |
アールエックスアイ ファーマシューティカルズ コーポレーション |
核酸分子を利用する目の前部における障害の処置のための方法
|
WO2015175510A1
(en)
|
2014-05-12 |
2015-11-19 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating a serpinc1-associated disorder
|
JP6811094B2
(ja)
|
2014-05-22 |
2021-01-13 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
アンジオテンシノーゲン(AGT)iRNA組成物およびその使用
|
ES2877099T3
(es)
|
2014-07-10 |
2021-11-16 |
Hibercell Inc |
Beta-glucano en combinación con agentes anticáncer que afectan al microambiente tumoral
|
KR102506169B1
(ko)
|
2014-09-05 |
2023-03-08 |
피오 파마슈티칼스 코프. |
Tyr 또는 mmp1을 표적화하는 핵산을 사용한 노화 및 피부 장애의 치료 방법
|
WO2016038550A1
(en)
|
2014-09-11 |
2016-03-17 |
Novartis Ag |
Inhibition of prmt5 to treat mtap-deficiency-related diseases
|
EP3191591A1
(en)
|
2014-09-12 |
2017-07-19 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting complement component c5 and methods of use thereof
|
WO2016061487A1
(en)
|
2014-10-17 |
2016-04-21 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
|
EP3904519A1
(en)
|
2014-10-30 |
2021-11-03 |
Genzyme Corporation |
Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof
|
CN107106593B
(zh)
|
2014-11-06 |
2021-05-07 |
百奥赛诺公司 |
影响肿瘤微环境的β-葡聚糖方法与组合物
|
US10479997B2
(en)
|
2014-12-01 |
2019-11-19 |
Novartis Ag |
Compositions and methods for diagnosis and treatment of prostate cancer
|
KR20240013283A
(ko)
|
2014-12-03 |
2024-01-30 |
애질런트 테크놀로지스, 인크. |
화학적 변형을 갖는 가이드 rna
|
AU2015364508A1
(en)
|
2014-12-18 |
2017-07-06 |
Alnylam Pharmaceuticals, Inc. |
ReversirTM compounds
|
JP6873911B2
(ja)
|
2015-04-06 |
2021-05-19 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
初代細胞において標的核酸の遺伝子調節を誘導するためにインビトロで行う方法
|
EP3302525A2
(en)
|
2015-06-05 |
2018-04-11 |
Novartis AG |
Methods and compositions for diagnosing, treating, and monitoring treatment of shank3 deficiency associated disorders
|
EP4365291A2
(en)
|
2015-06-12 |
2024-05-08 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions and methods of use thereof
|
EP3310918B1
(en)
|
2015-06-18 |
2020-08-05 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
|
WO2016209862A1
(en)
|
2015-06-23 |
2016-12-29 |
Alnylam Pharmaceuticals, Inc. |
Glucokinase (gck) irna compositions and methods of use thereof
|
US10808247B2
(en)
|
2015-07-06 |
2020-10-20 |
Phio Pharmaceuticals Corp. |
Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
|
CN108135923B
(zh)
|
2015-07-06 |
2021-03-02 |
菲奥医药公司 |
靶向超氧化物歧化酶1(sod1)的核酸分子
|
US10494632B2
(en)
|
2015-07-10 |
2019-12-03 |
Alnylam Pharmaceuticals, Inc. |
Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof
|
KR20180037297A
(ko)
|
2015-08-31 |
2018-04-11 |
애질런트 테크놀로지스, 인크. |
상동 재조합에 의한 crispr/cas-기반 게놈 편집을 위한 화합물 및 방법
|
CN108368507B
(zh)
|
2015-09-02 |
2022-03-22 |
阿尔尼拉姆医药品有限公司 |
程序性细胞死亡1配体1(PD-L1)的iRNA组合物及其使用方法
|
WO2017044832A1
(en)
|
2015-09-09 |
2017-03-16 |
Omnigen Research, Llc |
A composition and/or combination for aquaculture
|
EP3365446A4
(en)
|
2015-10-19 |
2019-06-26 |
Phio Pharmaceuticals Corp. |
SELF ADMINISTRATION-REDUCED SIZE NUCLEIC ACID COMPOUNDS TARGETING LONGS NON-CODING LONGS
|
US10767175B2
(en)
|
2016-06-08 |
2020-09-08 |
Agilent Technologies, Inc. |
High specificity genome editing using chemically modified guide RNAs
|
US20190256845A1
(en)
|
2016-06-10 |
2019-08-22 |
Alnylam Pharmaceuticals, Inc. |
COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
|
EP3484450A4
(en)
*
|
2016-07-18 |
2020-04-01 |
Tissuegen, Inc. |
METHODS AND COMPOSITIONS FOR MAINTAINING THE CONFORMATION AND STRUCTURAL INTEGRITY OF BIOMOLECULES
|
US20180245065A1
(en)
|
2016-11-01 |
2018-08-30 |
Novartis Ag |
Methods and compositions for enhancing gene editing
|
EP3568162A1
(en)
|
2017-01-10 |
2019-11-20 |
Nektar Therapeutics |
Multi-arm polymer conjugates of tlr agonist compounds and related immunotherapeutic treatment methods
|
EP3568011B1
(en)
|
2017-01-10 |
2021-10-13 |
Unilever IP Holdings B.V. |
Biofilm targeting microcapsule carrying a non-volatile functional material
|
US11815435B2
(en)
|
2017-02-24 |
2023-11-14 |
Hibercell, Inc. |
Beta glucan immunopharmacodynamics
|
JP7277432B2
(ja)
|
2017-07-13 |
2023-05-19 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
乳酸脱水素酵素A(LDHA)iRNA組成物及びその使用方法
|
US11530413B2
(en)
|
2017-07-21 |
2022-12-20 |
Novartis Ag |
Compositions and methods to treat cancer
|
WO2019036031A2
(en)
|
2017-08-17 |
2019-02-21 |
Nektar Therapeutics |
IMMUNOTHERAPEUTIC METHOD FOR TUMOR TREATMENT
|
WO2019094578A1
(en)
|
2017-11-09 |
2019-05-16 |
Alnylam Pharmaceuticals Inc. |
Assays and methods for determining expression of the lect2 gene
|
WO2019094962A2
(en)
*
|
2017-11-13 |
2019-05-16 |
The Regents Of The University Of California |
Antimicrobial particles and sanitization methods
|
US10835581B2
(en)
|
2017-11-28 |
2020-11-17 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Method of treating insulin resistance
|
US11179412B2
(en)
|
2017-12-04 |
2021-11-23 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Methods of treating conditions involving elevated inflammatory response
|
GB201800417D0
(en)
*
|
2018-01-11 |
2018-02-28 |
Whelan Adam Owen |
Immunogenic agent and associated compositions, uses and methods
|
WO2019150309A1
(en)
|
2018-02-02 |
2019-08-08 |
Hammack Scott |
Modulators of gpr68 and uses thereof for treating and preventing diseases
|
US11667919B2
(en)
|
2018-02-22 |
2023-06-06 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Targeting cancer-associated long non-coding RNAs
|
CN110237249A
(zh)
*
|
2018-03-09 |
2019-09-17 |
南开大学 |
特异靶向树突状细胞的新型铝佐剂及在疫苗制备上的应用
|
WO2019178443A1
(en)
*
|
2018-03-16 |
2019-09-19 |
University Of Massachusetts |
Yeast cell wall particle encapsulation of biodegradable pro-payloads
|
EP3788138A1
(en)
|
2018-05-02 |
2021-03-10 |
Novartis AG |
Regulators of human pluripotent stem cells and uses thereof
|
EP3837367A1
(en)
|
2018-08-16 |
2021-06-23 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the lect2 gene
|
US20210332367A1
(en)
|
2018-09-18 |
2021-10-28 |
Alnylam Pharmaceuticals, Inc. |
KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
US10913951B2
(en)
|
2018-10-31 |
2021-02-09 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure
|
HRP20231338T1
(hr)
|
2018-12-20 |
2024-02-16 |
Vir Biotechnology, Inc. |
Kombinirana terapija hbv
|
NO346800B1
(en)
|
2019-06-28 |
2023-01-16 |
Ederagen As |
Deconstructed soil composition
|
CN114616331A
(zh)
|
2019-09-03 |
2022-06-10 |
阿尔尼拉姆医药品有限公司 |
抑制lect2基因表达的组合物和方法
|
EP4038189A1
(en)
|
2019-10-04 |
2022-08-10 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing ugt1a1 gene expression
|
WO2021087325A1
(en)
|
2019-11-01 |
2021-05-06 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing dnajb1-prkaca fusion gene expression
|
JP2023501445A
(ja)
|
2019-11-08 |
2023-01-18 |
フィオ ファーマシューティカルズ コーポレーション |
免疫治療のためのブロモドメイン含有タンパク質4(brd4)を標的とする化学修飾されたオリゴヌクレオチド
|
WO2021154941A1
(en)
|
2020-01-31 |
2021-08-05 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
|
JP2023514190A
(ja)
|
2020-02-10 |
2023-04-05 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
Vegf-a発現をサイレンシングするための組成物および方法
|
US20230092615A1
(en)
|
2020-02-21 |
2023-03-23 |
Mitotherapeutix Llc |
Compositions and methods for inhibiting expressing of methylation-controlled j-protein (mcj)
|
US20230190785A1
(en)
|
2020-03-30 |
2023-06-22 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing dnajc15 gene expression
|
KR20230008729A
(ko)
|
2020-04-06 |
2023-01-16 |
알닐람 파마슈티칼스 인코포레이티드 |
Myoc 발현을 사일런싱하기 위한 조성물 및 방법
|
WO2021207189A1
(en)
|
2020-04-07 |
2021-10-14 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing scn9a expression
|
US20230183707A1
(en)
|
2020-05-21 |
2023-06-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting marc1 gene expression
|
KR20230042023A
(ko)
|
2020-06-24 |
2023-03-27 |
비르 바이오테크놀로지, 인코포레이티드 |
조작된 b형 간염 바이러스 중화 항체 및 이의 용도
|
AU2022343300A1
(en)
|
2021-09-10 |
2024-04-18 |
Agilent Technologies, Inc. |
Guide rnas with chemical modification for prime editing
|
WO2024059165A1
(en)
|
2022-09-15 |
2024-03-21 |
Alnylam Pharmaceuticals, Inc. |
17b-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof
|